RLMD
NASDAQ · Pharmaceuticals
Relmada Therapeutics Inc
$6.84
-0.05 (-0.73%)
Open$6.72
Previous Close$6.89
Day High$7.03
Day Low$6.66
52W High$8.00
52W Low$0.52
Volume—
Avg Volume1.85M
Market Cap705.91M
P/E Ratio—
EPS$-1.15
SectorPharmaceuticals
Analyst Ratings
Strong Buy
11 analysts
Price Target
+446.3% upside
Current
$6.84
$6.84
Target
$37.37
$37.37
$22.23
$37.37 avg
$43.38
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 81.98M | 84.82M | 68.85M |
| Net Income | 12.35M | 12.13M | 11.14M |
| Profit Margin | 15.1% | 14.3% | 16.2% |
| EBITDA | 16.29M | 17.92M | 12.74M |
| Free Cash Flow | 15.25M | 10.32M | 8.64M |
| Rev Growth | +24.2% | +0.2% | +22.0% |
| Debt/Equity | 0.79 | 0.99 | 1.00 |
Pharmaceuticals Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| LLY | Eli Lilly and Co. | $1,107.08 | +0.45% | 40.9 | 1.03T |
| JNJ | Johnson & Johnson | $239.08 | +3.37% | 26.1 | 549.78B |
| MRK | Merck & Co. Inc. | $119.60 | +3.57% | 31.5 | 281.24B |
| PFE | Pfizer Inc. | $24.72 | -1.44% | 19.2 | 143.68B |
| BMY | Bristol-Myers Squibb Co | $55.53 | +1.52% | 18.5 | 110.27B |
| ZTS | Zoetis Inc | $76.84 | +1.25% | 12.5 | 33.00B |